<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0003613'>Antiphospholipid antibody</z:hpo> syndrome is an acquired <z:e sem="disease" ids="C0004364" disease_type="Disease or Syndrome" abbrv="">autoimmune disorder</z:e> characterized by vascular <z:mp ids='MP_0005048'>thrombosis</z:mp> and/or recurrent pregnancy losses along with laboratory evidence of <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Anticoagulation rather than immunosuppression is the mainstay of treatment </plain></SENT>
<SENT sid="2" pm="."><plain>Despite the effectiveness of oral anticoagulation for the prevention of recurrent thromboembolic episodes, thrombotic complications in the setting of apparently therapeutic oral anticoagulation have been observed; this may at times be due to difficulties in maintaining a consistently therapeutic level of anticoagulation </plain></SENT>
<SENT sid="3" pm="."><plain>Low-molecular-weight <z:chebi fb="5" ids="28304">heparin</z:chebi> has been a useful alternative for long-term anticoagulation when there is difficulty in managing oral <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> therapy and has the advantage of a consistent <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> effect </plain></SENT>
<SENT sid="4" pm="."><plain>In this report, we describe a woman with primary <z:hpo ids='HP_0003613'>antiphospholipid antibody</z:hpo> syndrome who developed extensive <z:hpo ids='HP_0002204'>pulmonary embolism</z:hpo> despite receiving a proven therapeutic dosage of low molecular weight <z:chebi fb="5" ids="28304">heparin</z:chebi> </plain></SENT>
</text></document>